Zelira Therapeutics (ASX:ZLD) Inventories, Raw Materials & Components: A$0.46 Mil (As of Jun. 2025)


What is Zelira Therapeutics Inventories, Raw Materials & Components?

Zelira Therapeutics ASX:ZLD Inventories, Raw Materials & Components is A$0.46 Mil as of Jun. 2025. The stock has 7 warning signs investors should review.

Zelira Therapeutics's inventories, raw materials & components for the quarter that ended in Jun. 2025 was A$0.46 Mil.

Zelira Therapeutics's quarterly raw materials declined from Jun. 2024 (A$1.20 Mil) to Dec. 2024 (A$0.00 Mil) but then increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.46 Mil).

Zelira Therapeutics's annual raw materials increased from Jun. 2023 (A$1.15 Mil) to Jun. 2024 (A$1.20 Mil) but then declined from Jun. 2024 (A$1.20 Mil) to Jun. 2025 (A$0.46 Mil).

Zelira Therapeutics Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Inventories, Raw Materials & Components Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.65 1.15 1.20 0.46

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.15 0.00 1.20 0.00 0.46

Zelira Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of A$0.46 Mil mean?
Zelira Therapeutics (ASX:ZLD) has a Inventories, Raw Materials & Components of A$0.46 Mil as of Jun. 2025. Raw materials are the components a company uses for its main products. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Inventories, Raw Materials & Components too high?
Zelira Therapeutics' current Inventories, Raw Materials & Components is A$0.46 Mil.
How does Zelira Therapeutics' Inventories, Raw Materials & Components compare to ENSC and PPCB?
Zelira Therapeutics' Inventories, Raw Materials & Components of A$0.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Inventories, Raw Materials & Components is A$0.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Inventories, Raw Materials & Components of A$0.46 Mil. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Inventories, Raw Materials & Components is A$0.46 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Inventories, Raw Materials & Components is A$0.46 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.